CORRECTION: NeuroSearch announces the issuance of an EHDN statement supporting the statistical conclusions on the primary endpoint of the MermaiHD study

Correction of NeuroSearch announcement no. 19-10 of 04.09.2010: 
The below bullet list, bullet no. 3., unfortunately mentioned a wrong date,
i.e. 28 March 2010. The correct date is 28 April 2010. This has been corrected
in the below text as well as in the attached corrected PDF file. 

-----------------------------------------------------------

Copenhagen, 4 September 2010 - Today, NeuroSearch A/S (NEUR) announced that the
European Huntington's Disease Network, EHDN, has issued a supportive statement
on the reported conclusions regarding the primary endpoint, the modified Motor
Score, mMS, of the MermaiHD study, following an independent EHDN panel review
of the statistical data and the analyses performed. The MermaiHD study is a
European Phase III study of Huntexil® (pridopidine) for Huntington's disease,
from which NeuroSearch reported the results earlier this year, consistent with
a beneficial effect on Huntington patients' motor function after 26 weeks'
treatment with Huntexil® (45 mg. twice daily). 
 
To ensure full transparency about the reported analyses of the primary
endpoint, NeuroSearch has agreed to make all data from the MermaiHD study and
the statistical analyses performed available to a panel of EHDN-associated
researchers for independent review. The review has been based on a quality
controlled draft of the statistical study report and led to the following
conclusions from the panel: 

1. The data were comprehensively described and found to be internally
consistent. 

2. The statistical methods used to describe and to interpret the study data
were overall adequate. 

3. The analysis of the primary endpoint in both the ‘full analysis set' (FAS)
population as well as in the ‘per protocol' (PP) population was correctly
reported in the NeuroSearch announcement from 28 April 2010. 

The statement was issued today in connection with the 6th  Plenary Meeting of
the EHDN, which is being held in Prague, Czech Republic from 3 - 5 September
and is available on the EHDN homepage in the section on Huntexil® (designated
by the project name; ACR16): www.euro-hd.net/html/projects/acr16. 

Prof. Bernhard Landwehrmeyer, Chairman of the EHDN, commented:
“I have confidence in NeuroSearch and the work they do in the area of
Huntington's disease. EHDN will remain committed to working with the company in
our shared aim to establish a better therapeutic offering for patients
suffering from this devastating disease.” 

A publication committee has drafted a manuscript containing a full account of
the findings from the MermaiHD study and intended for publication in a peer
reviewed journal. Once the final statistical report is available, the
manuscript will be reviewed, revised (as appropriate) and submitted. 


Thomas Hofman-Bang		Flemming Pedersen
Chairman 			CEO 		


Contact persons:

Flemming Pedersen, CEO: +45 2148 0118 

Hanne Leth Hillman, Vice President, Director of IR & Capital Market Relations,
telephone: +45 4017 5103 



About the MermaiHD study 
The MermaiHD study is a randomised, double-blinded and placebo-controlled Phase
III study conducted at 32 clinical centres across Europe to examine the effects
of Huntexil® on a number of Huntington's disease parameters. The study included
437 patients with Huntington's disease from Austria, Belgium, France, Germany,
Italy, Portugal, Spain and the UK. 

In the study, patients were randomly allocated to receive treatment with one of
two Huntexil® doses (45 mg. once or twice daily) or placebo during a 26-week
period. Patients completing the randomised phase have been offered to continue
into a 26-week open-label extension phase, in which they receive treatment with
45 mg. Huntexil® twice daily, only. 
 
The primary study endpoint is voluntary motor function in Huntington patients,
measured on the modified Motor Score (mMS), which is defined as the sum score
of voluntary motor items (items 4-10 and items 13-15) from the Total Motor
Score (TMS), The TMS includes 15 items of motor assessment and comprises the
motor part of the Unified Huntington's Disease Rating Scale (UHDRS), including
both voluntary motor function (mMS and eye movements) and involuntary movements
such as dystonia and chorea. TMS is also included as endpoint in the MermaiHD
study. Other endpoints include cognitive function, behaviour and symptoms of
depression and anxiety. 

About Huntexil® (pridopidine) 
Pridopidine acts as a dopaminergic stabiliser and is the first compound in a
new class of pharmaceutical agents, dopidines,to have demonstrated clinical
effect. Dopidines have the unique ability to stabilise the dopaminergic system,
i.e., to either enhance or inhibit dopamine dependent functions in the brain,
depending on the initial level of dopaminergic activity. 

Pridopidine inhibits dopamine activation of the D2 receptor with a preference
towards the high affinity (activated) receptor state and has no detectable
agonist activity on this receptor. In vivo, pridopidine strengthens glutamate
function in the frontal cortex, which may add to the agent's powerful
behavioural effects in states of excessively high dopamine activity or
excessively low glutamate activity, while not affecting behaviour under normal
conditions. Together, these findings suggest that pridopidine stabilises
psychomotor activity in states of hypo- and hyperactivity by means of
functional D2 antagonism and strengthening of cortical glutamate functions. 


About NeuroSearch - Company profile
NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical
company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business
is development of novel drugs to treat diseases of the central nervous system,
and the pipeline comprises eight products in clinical development (Phase
I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase
III development for the treatment of Huntington's disease, and tesofensine
ready for Phase III development as a novel treatment of obesity. 
 
NeuroSearch is founded on a well-established drug discovery platform in the
field of ion channels and monoamine transporters, ensuring the continuous
production of novel preclinical development candidates. The company has
strategic drug discovery alliances with Janssen Pharmaceutica and Eli Lilly as
well as a licence collaboration with Abbott. Further, NeuroSearch has equity
interests in a number of private companies in the Life Science industry.